
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+3
Beijing CorreGene Biotechnology Co., Ltd., founded by several Peking University alumni, dedicated to the development of innovative therapeutics based on T-cell receptors (TCRs). CorreGene has established a comprehensive research and development platform for T cell receptor (TCR) technology, incorporating breakthroughs in TCR cloning and affinity optimization. Inparticular, the proprietary SMART-TCR affinity optimization platform, a revolutionarytechnology in TCR affinity optimization, has significantly increased thesuccess rate and efficiency of TCR optimization. This groundbreaking platformhas effectively overcome previous barriers in the development of TCR-basedmedications. Currently, CorreGene is developing multiple First-in-class TCR-T cell therapies and TCR bispecifics, including the pioneering cell therapy drug targeting...
Tcr-t cell therapy,tcr bispecific antibody drugs,kras g12v/d,tcr affinity optimization,solid tumor,cell therapy,hpv ,and magea1
Corregene biotechnology operates in the Biotechnology research industry.
Corregene biotechnology's revenue is 11m - 100m
Corregene biotechnology has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.